Wang X, Li W, Marcus J, Pearson M, Song L, Smith K, et al
The discrepancy between demonstrated subcutaneous efficacy (or lack thereof) and marketed oral supplements creates a fundamental problem: commercially available AOD-9604 supplements likely deliver negligible systemic peptide due to oral bioavailability limitations
-
The transdermal compositions release GHK-Cu / copper tripeptide in various release patterns to allow 1-7 times delivery of GHK-Cu / copper tripeptide in a week
Converting between formulations and products If you switch pharmacies, switch from compounded to brand-name tirzepatide, or switch from semaglutide to tirzepatide, the dose conversion requires attention
Thorne also sells a stronger version of SynaQuell called SynaQuell+, which increases the doses of most ingredients and adds a few more to go with it